| T60076 |
Oritinib
|
2035089-28-0
|
98%
|
|
|
Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (d7...
|
| T5437 |
Gefitinib-based PROTAC 3
|
2230821-27-7
|
98%
|
|
|
Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(...
|
| T21853 |
(E)-AG 556
|
133550-41-1
|
98%
|
|
|
AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
|
| T34602 |
Selatinib
|
1275595-86-2
|
98%
|
|
|
Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.
|
| T3659 |
Zorifertinib
|
1626387-80-1
|
98%
|
|
|
Zorifertinib (AZD3759) is an orally active, effective and central nervous system-penetrant EGFR inhibitor. The IC50 values were 0.2, 0.3 and 0.2 nM for EGFR L858...
|
| T10531 |
BGB-102
|
807640-87-5
|
98%
|
|
|
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular deg...
|
| T11162 |
EGFR-IN-8
|
2407957-87-1
|
98%
|
|
|
EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC....
|
| T3870 |
Cyasterone
|
17086-76-9
|
98%
|
|
|
Cyasterone (Cyasteron), a natural EGFR inhibitor, can inhibit the growth of A549 and MGC823 cells, via regulating EGFR signaling pathway, it may be a promising a...
|
| T76890 |
Petosemtamab
|
2213450-26-9
|
98%
|
Petosemtamab
|
|
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption...
|
| T76796 |
Patritumab
|
1262787-83-6
|
98%
|
|
|
Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritu...
|
| T6918 |
Olmutinib
|
1353550-13-6
|
98%
|
|
|
Olmutinib (HM61713, BI 1482694) is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential ant...
|
| T16492 |
PF-06459988
|
1428774-45-1
|
98%
|
|
|
PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor. PF-06459988 has high effi...
|
| T6036 |
Brivanib
|
649735-46-6
|
98%
|
|
|
Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR...
|
| T9927 |
Panitumumab
|
339177-26-3
|
98%
|
Panitumumab
|
|
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
|
| T5656 |
(±)-Norcantharidin
|
29745-04-8
|
|
|
|
(±)-Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
|
| T1761 |
PD153035 hydrochloride
|
183322-45-4
|
|
|
|
PD153035 hydrochloride (ZM 252868) is a effective and selective inhibitor of EGFR (Ki: 5.2 pM, IC50: 29 pM); few influence against FGFR, PGDFR, InsR, CSF-1, and ...
|
| T0078L |
Lapatinib ditosylate monohydrate
|
388082-78-8
|
|
|
|
Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumor...
|
| T2116 |
AEE788
|
497839-62-0
|
|
|
|
AEE788 (NVP-AEE 788) has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
| T4612 |
NS309
|
18711-16-5
|
|
|
|
NS309 is a nonselective activator of small- and intermediate-conductance Ca2+-activated K+ (SK/KCa2 and IK/KCa3.1) channels (EC50s range from 0.12-1.2 µM for SK ...
|
| T6145 |
ZM39923 hydrochloride
|
1021868-92-7
|
|
|
|
ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be ...
|
